Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback